Englitazone is a thiazolidinedione antidiabetic agent. It has insulinomimetic and insulin-enhancing actions in vitro and glucose-, insulin-, triglyceride-, and cholesterol-lowering properties in an animal model of non-insulin-dependent diabetes mellitus. It acts as a peroxisome-proliferator-activated receptor-gamma ligand. Englitazone inhibits ATP-sensitive potassium and calcium-activated non-selective cation channels in a voltage-independent manner.

Pyrroliphene is a dialkylaminodiphenylbutanol ester with antitussive and analgesic activities. In clinical trials the major side effect of Pyrroliphene was sedation, and the other side effect liabilities were similar to those of morphine.

Rivoglitazone hydrochloride (CS-011) is a thiazolidinedione-derivative peroxisome proliferator–activated receptor (PPAR)-γ agonist. It has been developed as potential treatment in type 2 diabetes mellitus and was shown to decrease plasma glucose and triglyceride levels in a dose-dependent manner in animals. Phase II and III clinical studies have assessed the efficacy and safety of rivoglitazone hydrochloride in patients with type 2 diabetes mellitus.

Benhepazone (also known as RCH-314) possessed potent analgesic and anti-inflammatory activities. Information about the nowadays use of this compound is not available.

FEPRADINOL is an analgesic, antipyretic and anti-inflammatory agent. Its anti-inflammatory activity does not seem to be related to an inhibitory effect on prostaglandin biosynthesis.

Imoxiterol (also known as RP 58802B) is benzimidazole derivatives patented by pharmaceutical company Laboratoire Roger Bellon S. A as a long-acting β-adrenergic agonist. In preclinical models, nebulized Imoxiterol produced a rapid onset and long-lasting inhibition of histamine-induced bronchospasm in the anaesthetized guinea-pig. Given orally, Imoxiterol produced a greater than three-fold shift to the right of the dose-response curve and depressed the maximum response to histamine. Imoxiterol prevented the development of bronchial hyperreactivity. Although PAF-induced bronchial hyperreactivity was not accompanied by an increase in the number of pulmonary eosinophils, Imoxiterol reduced the numbers of eosinophils recovered by lavage. Imoxiterol significantly inhibited PAF-induced microvascular leakage into guinea-pigs lung.

Brecanavir (previously known as VX-385), a HIV aspartyl protease inhibitor was developed for the treatment of HIV. The inhibition of HIV viral proteinase enzyme prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. Brecanavir reached Phase II development. However, GlaxoSmithKline announced to discontinue development brecanavir. Because of the inability to develop a viable oral dosage formulation capable of delivering the desired brecanavir levels in patients with multi-drug resistant HIV.

Benzetimide, a muscarinic acetylcholine receptor antagonist that was investigated as an antiparkinson-agent and was studied in the treatment of diarrheas of cattle and calves. Benzetimide is an enantiomer of dexetimide that has been used to treat neuroleptic-induced Parkinsonism.

LEDAZEROL is a derivative of mivazerol. It was under development as an antianginal agent.

Metaterol is a beta-adrenoceptor agonist. It exerts sympathomimetic and broncholytic properties.